Company News-宜明昂科英文

Company News

Company News

Company News

ImmuneOnco Regains Global Rights to IMM2510/AXN-2510 and IMM27M/AXN-27M Following Axion Bio's Discontinuation

SHANGHAI, January 6, 2026 -- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) ("ImmuneOnco") today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc.,

ImmuneOnco R&D Vice President Mr. Li Song Selected for Shanghai's 2025 "Oriental Talent Program"

Recently, the list of selected candidates for the 2025 Shanghai "Oriental Talent Program" (Top Tier) was officially announced. Mr. Li Song, Vice President of Research and Development at ImmuneOnco Bio

ImmuneOnco Successfully Holds Interim Investigator Meeting in Beijing for Phase Ib/II Clinical Study of Amulirafusp Alfa (IMM0306) Injection in Active Systemic Lupus Erythematosus

ImmuneOnco successfully convened the interim investigator meeting for the "Phase Ib/II Clinical Study of Amulirafusp Alfa (IMM0306) Injection in Active Systemic Lupus Erythematosus (SLE)" in Beijing.

2025 ASH | ImmuneOnco Announces Positive Progress from Phase I/II Study of IMM0306 Combined with Lenalidomide for Relapsed/Refractory CD20-Positive Follicular Lymphoma

December 9, 2025 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco", Hong Kong Stock Exchange code: 01541.HK) today announced that the company presented data from

ImmuneOnco's Amulirafusp Alfa (IMM0306) Phase III Clinical Trial Protocol Approved by CDE, Accelerating Development of Novel Therapy for Relapsed/Refractory Follicular Lymphoma

Amulirafusp Alfa (IMM0306), in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (FL), has been formally approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)

Positive Progress of Amulirafusp Alfa (IMM0306) in the Treatment of Systemic Lupus Erythematosus (SLE) Presented at ACR Convergence 2025

On October 28, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco," with the stock code 01541.HK on the Hong Kong Stock Exchange) presented the latest results of the Phase

总计 95 1 234 5 6 7 8...15 16